Pharma recovery on track; near-term earnings under pressure

Pharma ₹233Cr revenue (Q1 is transition quarter); overall 5.9% YoY growth confirms Pharma outpaced Crop

Divisional margins may improve, but company EBITDA 9.2%, PAT -1.8% due to ₹50Cr+ interest on ₹685Cr net debt

No contradicting evidence; claim is credible and supported by re-approval narrative

Q1 is trough (5.9% YoY) due to FDA shutdown. Q2+ expected to recover substantially. Guidance conditional on recovery execution.

Prior call: 'positive volume growth in both segments.' Q1 call: 'very marginal growth, mid-to-high single digit.' End-customer weakness (5–6 big players = 80% of market) is structural, not cyclical.

Q1 call: Pharma expected 18–19% CAGR (vs company 14–16%). Prior call did not quantify divisional CAGR. CDMO acceleration and new geographies (Japan, Latin America) are the driver.

Prior call: 'entering Personal Care, scaling Animal Health.' Q1 call: Personal Care ₹200Cr, >20% EBITDA by 3 years; Animal Health ₹400Cr, 20%+ EBITDA by FY30. Concrete targets introduced.

Management: 'real meaningful numbers will be in FY28 and beyond' due to remediation cost removal. FY27 remains a transition year. Not a change to guidance, but a reframing of expectations.

20% plus EBITDA margins once operational leverage is reached.

Very marginal growth (mid-to-high single digit). End-customers (5–6 big players = 80% of market) are weak. Diversifying into Animal Health, Personal Care; not investing significant new capital in Crop.

Yes. Shifting to 4-division model (Pharma, Animal Health, Personal Care, Crop). Pharma + allied (human + non-human + skincare) = 70–80% of business by next 2–3 years; Crop = 20–30%.

₹200Cr revenue by 3 years post-launch (i.e., by FY30). EBITDA margins >20%, in line with Pharma.

FY27 is a transition year; FDA remediation costs are depressing fixed costs and EBITDA. Once remediation ends, FY28 onwards EBITDA will improve substantially. Real meaningful numbers in FY28+.

Guidance will accelerate in FY28 due to pending approvals. Filings pending FDA approval will be completed post-remediation, driving revenue ramp in FY28 with better margins.

Some contracts have pass-through; competitive ones don't. End-customer (farmer) prices don't increase much; no price elasticity. In Q1 alone, ₹7–8Cr raw material/energy cost impact. Mixed bag; hoping oil prices stabilize.

Expecting 15–16% CAGR to continue. Fixed costs won't scale at this level; next year remediation cost benefit will improve P&L. FY28 substantially better than FY27, which is better than FY26.

Stage-gate approach; continuous dialogue with FDA on bi-monthly/quarterly basis. FDA feedback: moving in right direction, few open issues to close. After August 2025 warning, 3 big regulatory bodies and 86 customers have audited and re-approved. Putting controls, systems, training, SOPs, continuous audits.

CAGR will improve. If company is at 14–15% CAGR, Pharma will be 18–19% CAGR going forward, maybe even faster if approvals ramp and NCE filings accelerate.

₹400Cr revenue by FY30, based on strategic plan and current customer traction.

Globally agnostic. Customers are pharma innovators, so sell to all markets where they sell: US, Europe, Japan, ROW (Latin America, etc.).

Q1 is trough (5.9% YoY); Q2+ expected substantial recovery. Q2 specifically called as 'substantial growth' YoY. H2 benefiting from CDMO ramp, Crop normalization, Personal Care launch.

Q2-Q4 recovery expected to drive ≥20% EBITDA margins in H2. Pharma gross margin improving, Crop cost headwinds expected to moderate. Personal Care/Animal Health ramp supports leverage.

New geographies (Japan, Latin America), NCE filings accelerating, CDMO partnerships. But contingent on FDA clearance and no further customer losses.

4-year ₹900Cr investment program (₹300Cr maintenance, ₹600Cr growth). Retooled Crop asset now serving Pharma/Animal Health, reducing execution time by 12 months. ROI-focused allocation.

Remediation plan on track but re-inspection depends on FDA scheduling. If delayed beyond Q4 FY27, remediation costs extend, margin recovery pushed to FY29.

Industry end-customers (5–6 big pharma/agrochemical players = 80% of market) are weak; pricing under pressure; Chinese supply creates race-to-bottom. Management acknowledges 'very marginal growth' (mid-to-high single digit) going forward. Q1 margins already negative (-₹6Cr EBIT) due to ₹7–8Cr raw material cost.

Q1 saw ₹7–8Cr cost impact from geopolitical tensions in Middle East (fuel, raw material costs). If tensions persist or escalate, EBITDA growth target of 25–30% becomes unachievable.

Company generated ₹37Cr EBITDA but lost ₹7.4Cr in PAT due to ₹50Cr+ annual interest on net debt. Even if EBITDA grows to ₹46–50Cr (25–30% growth), PAT may remain negative if interest costs don't decline. Leverage is the primary margin headwind.

Animal Health targeting ₹400Cr by FY30 (4x from ₹100Cr FY26) at 20%+ EBITDA. Personal Care targeting ₹200Cr by FY30 with >20% EBITDA. Both are new/emerging; scale and margin realization unproven. Dependence on CDMO contract wins, customer commercialization timelines, market acceptance.